Xilonibsa with Epinephrine Dosage

Did you have any side effects with this medicine?
sponsored

Dosage of Xilonibsa with Epinephrine in details

The dose of a drug and dosage of the drug are two different terminologies. Dose is defined as the quantity or amount of medicine given by the doctor or taken by the patient at a given period. Dosage is the regimen prescribed by the doctor about how many days and how many times per day the drug is to be taken in specified dose by the patient. The dose is expressed in mg for tablets or gm, micro gm sometimes, ml for syrups or drops for kids syrups. The dose is not fixed for a drug for all conditions, and it changes according to the condition or a disease. It also changes on the age of the patient.
sponsored

Apply one Xilonibsa with Epinephrine™ (0.5 mg Xilonibsa with Epinephrine hydrochloride monohydrate) to the site planned for venipuncture or intravenous cannulation, one to three minutes prior to needle insertion.

Perform the procedure within 10 minutes after Xilonibsa with Epinephrine™ (lindocaine hydrochloride monohydrate) administration.

Use Xilonibsa with Epinephrine™ (lindocaine hydrochloride monohydrate) only on intact skin.

Application of one additional Xilonibsa with Epinephrine™ (lindocaine hydrochloride monohydrate) at a new location is acceptable after a failed attempt at venous access. Multiple administrations of Xilonibsa with Epinephrine™ (lindocaine hydrochloride monohydrate) at the same location are not recommended.

When Xilonibsa with Epinephrine™ (lindocaine hydrochloride monohydrate) is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all sources should be considered, as local anesthetics are thought to have at least additive toxicities.

Instructions for Use

Prepare the Treatment Site and Device: Examine the treatment site to ensure that the skin is intact. Clean the site, according to standard practice.

Visually inspect the pouch. Do not use if the pouch has been torn, or damaged or if the device has been dropped.

Tear open the pouch using the notch provided (Figure 1a). Remove Xilonibsa with Epinephrine™ (lindocaine hydrochloride monohydrate) from the pouch, being careful not to touch the purple outlet (open end) to avoid contamination. (Figure 1b).

Figure 1a

Figure 1b

Position Xilonibsa with Epinephrine™ (lindocaine hydrochloride monohydrate) : Grip Xilonibsa with Epinephrine™ (lindocaine hydrochloride monohydrate) and place on the application site, with one hand, as illustrated in Figure 2, or with both hands, as shown in Figure 3.

Figure 2

Figure 3

Ensure that the patient's treatment site is supported to prevent movement. Seal the purple Xilonibsa with Epinephrine™ (lindocaine hydrochloride monohydrate) outlet against the patient's skin. Hold the device perpendicular to the skin, making sure that your thumb can reach the green start button.

Avoid gaps between the skin and the Xilonibsa with Epinephrine™ (lindocaine hydrochloride monohydrate) outlet, like the one illustrated in Figure 4, as gaps will impede drug delivery.

Figure 4

Release the Safety Interlock: Apply adequate downward pressure to release the safety interlock, while maintaining the seal between Xilonibsa with Epinephrine™ (lindocaine hydrochloride monohydrate) and the skin.

Xilonibsa with Epinephrine™ (lindocaine hydrochloride monohydrate) is ready for administration when the green start button has moved into the upward position, as illustrated in Figure 5a.

Figure 5a

Xilonibsa with Epinephrine™ (lindocaine hydrochloride monohydrate) cannot be actuated without releasing the internal safety interlock, as illustrated in Figure 5b.

Figure 5b

Administer Xilonibsa with Epinephrine™ (lindocaine hydrochloride monohydrate) : While maintaining downward pressure, administer the dose by pressing the green start button, as illustrated in Figure 6. Do not move Xilonibsa with Epinephrine™ (lindocaine hydrochloride monohydrate) during administration. Actuation is accompanied by a “popping” sound, indicating that the dose has been discharged.

Figure 6

Remove Xilonibsa with Epinephrine™ (lindocaine hydrochloride monohydrate) : Remove Xilonibsa with Epinephrine™ (lindocaine hydrochloride monohydrate) from the application site and dispose.

Begin Procedure: Start the venipuncture or intravenous cannulation procedure 1–3 minutes after Xilonibsa with Epinephrine™ (lindocaine hydrochloride monohydrate) administration.

How supplied

Dosage Forms And Strengths

Xilonibsa with Epinephrine™ (Xilonibsa with Epinephrine hydrochloride monohydrate) powder intradermal injection system contains 0.5 mg of sterile Xilonibsa with Epinephrine hydrochloride monohydrate.

NDC 28000-105-12 Xilonibsa with Epinephrine™ (Xilonibsa with Epinephrine hydrochloride monohydrate) powder intradermal injection system contains 0.5 mg of sterile Xilonibsa with Epinephrine hydrochloride monohydrate. Xilonibsa with Epinephrine™ (lindocaine hydrochloride monohydrate) is a single-use device packaged in an individual foil/clear pouch placed inside a bubble-wrap sleeve. Twelve sleeves are placed in labeled cartons.

Cartons are stored at controlled room temperature (15-30°C, 59-86°F).

Manufactured for: Anesiva, Inc. South San Francisco, CA 94080. Distributed by: Sagent Pharmaceuticals, Inc. Schaumburg, IL 60195.

What other drugs will affect Xilonibsa with Epinephrine?

Tell your doctor about all other medicines you use, especially:

This list is not complete and other drugs may interact with Xilonibsa with Epinephrine. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.

Xilonibsa with Epinephrine interactions

Interactions are the effects that happen when the drug is taken along with the food or when taken with other medications. Suppose if you are taking a drug Xilonibsa with Epinephrine, it may have interactions with specific foods and specific medications. It will not interact with all foods and medications. The interactions vary from drug to drug. You need to be aware of interactions of the medicine you take. Most medications may interact with alcohol, tobacco, so be cautious.
sponsored

Beta-blockers increase the risk of bradycardia and hypotension. Norepinephrine and beta-blockers by reducing hepatic blood flow decrease (increased toxicity), isadrine and glucagon - increase the clearance of Xilonibsa with Epinephrine. Cimetidine increases the plasma concentration of Xilonibsa with Epinephrine Haffkine Bio-Pharmaceutical Corporation (displaces from its association with proteins and slows inactivation in the liver). Barbiturates causing induction of microsomal enzymes stimulate the degradation of Xilonibsa with Epinephrine and reduce its activity. Anticonvulsants (hydantoin derivatives) accelerate the biotransformation in the liver (decreased concentration in the blood), for IV injections it may increases cardiodepressive action of Xilonibsa with Epinephrine. Antiarrhythmics (amiodarone, verapamil, quinidine, aymalin) potentiate cardiac depression. Combination with novocainamide may cause CNS excitement and hallucinations. Xilonibsa with Epinephrine Haffkine Bio-Pharmaceutical Corporation strengthens the inhibitory effect of anesthesia (hexobarbital, thiopental sodium), hypnotics and sedatives on the respiratory center, weakens the cardiac effects of digitoxin, enhances muscle relaxation caused by drugs curare like (possible paralysis of respiratory muscles). MAO inhibitors prolong local anesthesia.


sponsored

References

  1. DailyMed. "LIDOCAINE; TETRACAINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. FDA/SPL Indexing Data. "98PI200987: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
  3. MeSH. "Anti-Arrhythmia Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Xilonibsa with Epinephrine are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Xilonibsa with Epinephrine. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported frequency of use

No survey data has been collected yet


Consumer reported doses

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 28 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2024 ndrugs.com All Rights Reserved